Ezetimibe Tablets, USP 10mg (Camber, USA)

Ezetimibe administered alone, or with an HMG-CoA reductase inhibitor (statin), is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia.

Ezetimibe, administered with a statin, is indicated for patients with Homozygous Familial Hypercholesterolaemia (HoFH). Patients may also receive adjunctive treatments (e.g., LDL apheresis).

Ezetimibe is indicated for the reduction of elevated sitosterol and campesterol levels in patients with Homozygous Familial Sitosterolaemia (Phytosterolaemia).

Ezetimibe co-administered with simvastatin (doses up to 40 mg) is indicated as an adjunctive therapy to diet in adolescent patients (10-17 years old) with Heterozygous Familial Hypercholesterolaemia (HeFH) where use of a combination product is appropriate:

• Patients not appropriately controlled with a statin or ezetimibe alone
• Patients already treated with a statin and ezetimibe

Ezetimibe co-administered with simvastatin (doses up to 40 mg) is indicated in adolescent patients (10-17 years old) with Homozygous Familial Hypercholesterolaemia (HoFH). Patients may also receive adjunctive treatments (e.g. LDL apheresis).